US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Another venture funding surge sets up a strong 2018
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
